The headline-grabbing field of immuno-oncology holds promises and challenges. Informative yet general articles (like this) reinforce what those who have spent decades in and around the industry have come to expect:
- Significant capital
- Intense competition
- Lengthy approval timelines
- High sales expectation
- Higher company valuations
- Need for patient stratification
- And, most importantly, the possibility for profound impact on human health
But the current immunotherapies don’t benefit all patients—a limitation spurring the industry to hunt for new ways to push immune cells to destroy tumors. Companies big and small are racing to develop these new medicines, which analysts say could help boost global cancer immunotherapy sales to more than $40 billion a year by the middle of the next decade, from more than $6 billion in 2016.
https://www.wsj.com/articles/race-tightens-for-next-wave-of-cancer-drugs-1488796210
unknownx500
